or Try an Advanced Search...

    Hepatitis C Virus Infection Stocks List

    Symbol Grade Name % Change
    BMY F Bristol-Myers Squibb Company -0.18
    IONS F Ionis Pharmaceuticals, Inc. -0.82
    RGLS F Regulus Therapeutics Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Hepatitis C Hepatitis C Virus Biopharmaceutical Diabetes Dystrophy Genetics Hepatitis B Hepatitis B Virus Lipodystrophy Treatment Of Diabetes Acromegaly Alcohol Alnylam Pharmaceuticals Alport Syndrome Amyloid Amyloidosis Angioedema Antisense RNA Apatorsen Atherosclerosis

    Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C Virus Infection stocks.

    Symbol Grade Name Weight
    FTXH B First Trust Nasdaq Pharmaceuticals ETF 6.83
    MEDX D Horizon Kinetics Medical ETF 4.71
    WBIY B WBI Power Factor High Dividend ETF 4.34
    IHE C iShares U.S. Pharmaceutical ETF 3.93
    XPH D SPDR S&P Pharmaceuticals ETF 3.86
    View all Hepatitis C Virus Infection ETFs...
    Compare ETFs
    Compare FTXH to IHE Compare FTXH to MEDX Compare MEDX to WBIY

        Hepatitis C Virus Infection Stocks Recent News

        Date Stock Title
        May 17 IONS Ionis, Biogen Down on Ending Development of ALS Drug
        May 17 BMY AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
        May 17 IONS Ionis (IONS), Biogen Down on Ending Development of ALS Drug
        May 17 BMY The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
        May 17 BMY Erasca restructures; Novartis moves to complete MorphoSys deal
        May 17 BMY BMS reports four-year data from psoriasis treatment extension trial
        May 16 BMY Walmart Earnings & the State of the Consumer
        May 16 IONS Biogen also drops collaboration with Ionis on Angelman syndrome candidate
        May 16 BMY Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
        May 16 BMY New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
        May 16 IONS Biogen and Ionis drop ALS candidate after trial setback
        May 16 BMY Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
        May 16 RGLS Regulus Therapeutics names Rekha Garg as chief medical officer
        May 16 IONS Biogen, Ionis shelve ALS drug following study failure
        May 16 RGLS Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
        May 16 IONS REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
        May 16 IONS Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
        May 16 IONS Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
        May 16 IONS Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
        May 16 BMY FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Hepatitis C Hepatitis C Virus Biopharmaceutical Diabetes Dystrophy Genetics Hepatitis B Hepatitis B Virus Lipodystrophy Treatment Of Diabetes Acromegaly Alcohol Alnylam Pharmaceuticals Alport Syndrome Amyloid Amyloidosis Angioedema Antisense RNA Apatorsen Atherosclerosis
        Hepatitis C Virus Infection

        Hepatitis C virus (HCV) infection is a contagious liver disease caused by the hepatitis C virus. It is spread through contact with the blood of an infected person. Symptoms of HCV infection can range from mild to severe and may include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored stools, joint pain, and jaundice. In some cases, HCV infection can lead to serious liver problems, including cirrhosis and liver cancer. Treatment for HCV infection typically involves a combination of antiviral medications.

        Browse All Tags